XBiotech (XBIT) Competitors

Erasca (NASDAQ:ERAS) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, community ranking, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

Which has preferable earnings and valuation, ERAS or XBIT?

XBiotech has higher revenue and earnings than Erasca. XBiotech is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$125.04M	-$0.74	-1.64
XBiotech	$4.01M	22.43	-$24.56M	-$1.26	-2.34

Is ERAS or XBIT more profitable?

XBiotech's return on equity of -15.99% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-42.26%	-34.97%
XBiotech	N/A	-15.99%	-14.85%

Which has more volatility & risk, ERAS or XBIT?

Erasca has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500. Comparatively, XBiotech has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500.

Do analysts recommend ERAS or XBIT?

Erasca presently has a consensus target price of $4.83, suggesting a potential upside of 299.45%. Given Erasca's stronger consensus rating and higher possible upside, equities research analysts clearly believe Erasca is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
XBiotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Do institutionals and insiders hold more shares of ERAS or XBIT?

67.8% of Erasca shares are owned by institutional investors. Comparatively, 55.7% of XBiotech shares are owned by institutional investors. 21.5% of Erasca shares are owned by insiders. Comparatively, 33.1% of XBiotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Does the media favor ERAS or XBIT?

In the previous week, Erasca had 2 more articles in the media than XBiotech. MarketBeat recorded 3 mentions for Erasca and 1 mentions for XBiotech. XBiotech's average media sentiment score of 1.90 beat Erasca's score of 0.63 indicating that XBiotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
XBiotech	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Does the MarketBeat Community believe in ERAS or XBIT?

XBiotech received 288 more outperform votes than Erasca when rated by MarketBeat users. However, 74.36% of users gave Erasca an outperform vote while only 69.98% of users gave XBiotech an outperform vote.

Company	Underperform	Outperform
Erasca	Outperform Votes 29 74.36%	Underperform Votes 10 25.64%
XBiotech	Outperform Votes 317 69.98%	Underperform Votes 136 30.02%

Summary

Erasca and XBiotech tied by winning 8 of the 16 factors compared between the two stocks.